Cargando…

Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database

Objective: The introduction of Bruton’s tyrosine kinase (BTK) inhibitors was a milestone in the treatment of B-cell malignancies in recent years owing to its desired efficacy against chronic lymphocytic leukaemia and small cell lymphocytic lymphoma. However, safety issues have hindered its applicati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wan, Qing, Li, Qiang, Lai, Xin, Xu, Tiantian, Hu, Jinfang, Peng, Hongwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691840/ https://www.ncbi.nlm.nih.gov/pubmed/36438789 http://dx.doi.org/10.3389/fphar.2022.995522

Ejemplares similares

Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
por: Zhou, Xiang, et al.
Publicado: (2021)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
por: Liu, Wensheng, et al.
Publicado: (2023)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
por: Chen, Chenxin, et al.
Publicado: (2021)

Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS
por: Tang, Shu, et al.
Publicado: (2022)

Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
por: Feng, Zhen, et al.
Publicado: (2022)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database
por: Shu, Yamin, et al.
Publicado: (2022)

Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and pharmacovigilance assessment of the FAERS database
por: Liu, Leping, et al.
Publicado: (2023)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
por: Cui, Zhiwei, et al.
Publicado: (2023)

Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS
por: Wu, Bin, et al.
Publicado: (2022)

The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase
por: Battini, Vera, et al.
Publicado: (2023)

Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database
por: Allouchery, Marion, et al.
Publicado: (2021)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Electrolyte Disorders Associated with Piperacillin/Tazobactam: A Pharmacovigilance Study Using the FAERS Database
por: Seo, Heenam, et al.
Publicado: (2023)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
por: Li, Meng, et al.
Publicado: (2022)

Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS
por: Chai, Shuang, et al.
Publicado: (2022)

Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS
por: Tian, Xiaojiang, et al.
Publicado: (2022)

Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database
por: Ma, Z., et al.
Publicado: (2021)

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
por: Zhou, Chaozheng, et al.
Publicado: (2023)

Editorial: Leveraging pharmacovigilance data mining with “the patient” in mind
por: Gossell-Williams, Maxine, et al.
Publicado: (2022)

Mining and visualizing high-order directional drug interaction effects using the FAERS database
por: Yao, Xiaohui, et al.
Publicado: (2020)

Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study
por: Huang, Jing, et al.
Publicado: (2023)

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS
por: Schilder, Jeanne M., et al.
Publicado: (2023)

Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database
por: Xia, Shuang, et al.
Publicado: (2023)

Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS)
por: Yuan, Jing, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database
por: Ceschi, Alessandro, et al.
Publicado: (2020)

Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022
por: Wang, Yanfeng, et al.
Publicado: (2023)

Potential safety signals for antibacterial agents from the Brazilian national pharmacovigilance database (Vigimed/VigiFlow)
por: Barbosa, Luiza Hoehl Loureiro Alves, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
por: Ruggiero, Rosanna, et al.
Publicado: (2020)

Mining Patients' Narratives in Social Media for Pharmacovigilance: Adverse Effects and Misuse of Methylphenidate
por: Chen, Xiaoyi, et al.
Publicado: (2018)

A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases
por: Chiappini, Stefania, et al.
Publicado: (2022)

Inflammasome Targeted Therapy in Pregnancy: New Insights From an Analysis of Real-World Data From the FAERS Database and a Systematic Review
por: Carnovale, Carla, et al.
Publicado: (2021)

The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database
por: Yang, Huaju, et al.
Publicado: (2023)

Psychotropic drugs cross-reactivity with amphetamines in a FAERS sample: an international pharmacovigilance study
por: Giacovelli, L., et al.
Publicado: (2022)

Safety of Inulin and Sinistrin: Combining Several Sources for Pharmacovigilance Purposes
por: Bui, T-V., et al.
Publicado: (2021)

Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2019)

Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3oh5s7vljjpjarslvshdgb766k